Sinocare
8
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period
Role: lead
Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial
Role: lead
Mobile Health and Wearable Devices for Diabetes Complication Management
Role: collaborator
Continuous Glucose Monitoring System: Accuracy and Prognostic Value in Critically Ill Patients
Role: lead
The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus
Role: lead
Continuous Glucose Monitoring System Use in Pediatric Patients with Diabetes
Role: lead
Effect of CGM on Glucose Control in Non-insulin-treated Patients with Type 2 Diabetes Mellitus
Role: lead
Evaluate the Safety and Efficacy of Sinocare CGM System Regarding Real Time Glucose Level Monitoring
Role: lead
All 8 trials loaded